uniQure NV opened lower at $24.18, compared with its previous close of $24.59. In the last trading session, the stock traded between $24.01 and $26.20. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in uniQure NV is now worth
$ 75.20
Resulting in a loss of
$ 24.80 (24.80%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
80%
Hold
20%
Sell
0%
Markets Today
Today's Change
+$0.08 (+0.33%)
Day High
$26.20
Day Low
$24.01
Day Open
$24.18
Prev Close
$24.59
Volume
19,77,967
1W Return
7.06%
1M Return
12.80%
3M Return
-45.18%
6M Return
-10.76%
1Y Return
-20.02%
Fundamentals
Market Cap ($ Mn)
1,730
PE Ratio
-
PB Ratio
10.42
PEG Ratio
-
ROE
-220.80%
ROCE
-23.33%
EPS (TTM)
$-0.87
Investment Returns
1 Week
7.06%
1 Month
12.80%
3 Months
-45.18%
6 Months
-10.76%
9 Months
2.31%
Financials
Quarterly
All values in $ Mn
5.3
Jun 25
3.7
Sep 25
5.6
Dec 25
3.6
Mar 26
5.8
Jun 26
5.2
Sep 26
Updates
2Oct
RBC Capital maintains Outperform on uniQure, cuts price target to $48
RBC Capital analyst Luca Issi maintains Outperform rating on uniQure. Price target lowered from $65 to $48. Valuation cut amounts to a $17 reduction per share.
1mo ago
2Sep
uniQure files FDA BLA for accelerated approval of Huntington's gene therapy
uniQure filed a BLA with the FDA and an MAA with the UK MHRA for its Huntington's gene therapy ifezuntirgene inilparvovec. The applications are based on three-year Phase I/II data showing slowed disease progression compared to external controls. The drug holds Breakthrough Therapy, RMAT, and Fast Track designations from the FDA. uniQure requested priority review, which would reduce the FDA review cycle to six months.
2mo ago
30Jul
Barclays maintains Overweight on uniQure, cuts price target to $60
Barclays analyst Eliana Merle lowered the price target for uniQure (NASDAQ: QURE) from $65 to $60. The firm maintains its Overweight rating on the stock, indicating continued positive sentiment despite the reduced valuation ceiling.
3mo ago
29Jun
HC Wainwright maintains Buy on uniQure, raises target to $80
HC Wainwright & Co. analyst Patrick R. Trucchio maintained a Buy rating on uniQure and raised the price target to $80 from $50, signaling increased confidence in the company's growth.
4mo ago
18Jun
Goldman Sachs raises uniQure price target to $46
Goldman Sachs analyst Salveen Richter maintains a Neutral rating on uniQure and raises the price target from $14 to $46.
4mo ago
18Jun
Leerink Partners raises uniQure price target to $70
Leerink Partners analyst Joseph Schwartz maintained an Outperform rating on uniQure (NASDAQ: QURE) and raised the price target to $70 from $36. The adjustment signals a positive outlook on the company's future performance.
